Clinical Trial Update: Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluated insulin glulisine given before meals versus after meals in adults with Type 2 Diabetes Mellitus receiving basal insulin glargine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Apidra (insulin glulisine)
• Lantus (insulin glargine)

Snippet

Sponsor: Sanofi | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED